MindMed

Psychedelic Inspired Medicines

December 2021

NASDAQ	NEO	DE
MNMD	MMED	MMQ

Disclaimer

This presentation (the "Presentation") has been prepared by Mind Medicine (MindMed) Inc. ("MindMed" or the "Company") solely for informational purposes. None of MindMed, its affiliates or any of their respective employees, directors, officers, contractors, advisors, members, successors, representatives or agents makes any representation or warranty as to the accuracy or completeness of any information contained in this Presentation and shall have no liability for any representations (expressed or implied) contained in, or for any omissions from, this Presentation. This presentation shall not constitute an offer, nor a solicitation of an offer, of the sale or purchase of securities. This Presentation does not constitute an offering of securities of MindMed and under no circumstances is it to be construed as a prospectus or advertisement or public offering of securities.

Market and Industry Data

This Presentation by includes market and industry data that has been obtained from third party sources, including industry publications. MindMed believes that the industry data is accurate and that the estimates and assumptions are reasonable, but there is no assurance as to the accuracy or completeness of this data. Third party sources generally state that the information contained therein has been obtained from sources believed to be reliable, but there is no assurance as to the accuracy or completeness of included information. Although the data is believed to be reliable, MindMed has not independently verified any of the data from third party sources referred to in this Presentation or ascertained the underlying economic assumptions relied upon by such sources. References in this Presentation to research reports or to articles and publications should be not construed as depicting the complete findings of the entire referenced report or article. MindMed does not make any representation as to the accuracy of such information

Cautionary Note on Forward-Looking Information

This Presentation contains "forward-looking statements" and "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking information") with respect to MindMed and its subsidiaries. Statements in this Presentation that are forward-looking information are based on currently available competitive, financial, and economic data and operating plans as of the date of this Presentation but are subject to various risks and uncertainties concerning the specific factors disclosed herein. Often, but not always, forward-looking information can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", will", "projects", or "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events, results or conditions "may", "could", "would", "might" or "will" be taken, occur or be achieved. Except for statements of historical fact, information contained herein constitutes forward-looking information, including, but not limited to: statements pertaining to the development and commercialization of any medicine or treatment, or the efficacy of either of the foregoing, the likelihood of success of any clinical trials or of obtaining FDA or other regulatory approvals, the likelihood of obtaining patents or the efficacy of such patents once granted, and the potential for the markets that MindMed is anticipating to access.

Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management at the date the statements are made including among other things assumptions about: MindMed's ability to raise capital to complete its plans and fund its studies, the medical and commercial viability of the contemplated medicines and treatments being developed, and the ability of MindMed to raise additional capital in the future as MindMed continues to develop its products. While MindMed considers these assumptions to be reasonable, the assumptions are inherently subject to significant business, social, economic, political, regulatory, competitive and other risks and uncertainties, contingencies and other factors that could cause actual performance, achievements, actions, events, results or conditions to be materially different from those projected in the forward-looking information. These include the Company's history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; lack of revenue; compliance with laws and regulations; difficulty associated with research and development; risks associated with clinical trials or studies; heightened regulatory scrutiny; early stage product development; clinical trial risks; regulatory approval processes; novelty of the psychedelic inspired medicines industry; as well as those risk factors discussed or referred to under the headings "Risk Factors" in the Company's final base shelf prospectus dated April 9, 2021 filed with the securities regulatory authorities in each of the provinces and territories of Canada and the Company's annual information form for the year ended December 31, 2020 filed with the securities regulatory authorities in all provinces and territories of Canada and available under the Company's profile on SEDAR at www.sedar.com and as described in the Company's U.S. registration statement on Form F-10 declared effective by the United States Securities and Exchange Commission (the "SEC") on April 12, 2021 and filed with the SEC on EDGAR at www.sec.gov. Many assumptions are based on factors and events that are not within the control of MindMed and there is no assurance they will prove to be correct.

The United States federal government regulates drugs through the Controlled Substances Act. The Company works with a non-hallucinogenic synthetic derivative of the psychedelic substance ibogaine, known as "18-MC", which is a synthetic organic molecule designed around a common coronaridine chemical backbone. 18-MC is not a Schedule I substance in the United States and the Company does not foresee it becoming a Schedule I substance due to its non-hallucinogenic properties. While the Company is focused on programs using psychedelic inspired compounds and classic psychedelics, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates. The Company is a neuro-pharmaceutical drug development company and does not deal with psychedelic substances except within laboratory and clinical trial settings conducted within approved regulatory frameworks. The Company's products will not be commercialized prior to applicable regulatory approval, which will only be granted if clinical evidence of safety and efficacy for the intended uses is successfully developed.

Although MindMed has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking information, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: MindMed not being able to obtain the necessary FDA and other approvals, inconclusive or negative results from clinical trials, MindMed electing to not proceed with any of the medicines or treatments discussed herein, and MindMed not being able to build production capacity should its trials be successful. To the extent any forward-looking information contains forecasts or financial outlooks, such information is being provided solely to enable a reader to assess MindMed's financial condition and its operational history and experience in the pharmaceutical industry. Readers are cautioned that this information may be not appropriate for any other purpose, including investment decisions. Such information, as with forward-looking information generally, is, without limitation, based on the assumptions and subject to the risks and other cautionary statements set out above. The actual results achieved will vary from the forecast or financial outlook results and the variations may be material. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from, our projections or the assumptions underlying them.

There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. As a result of these risks and uncertainties, the results or events predicted in this forward-looking information may differ materially from actual results or events. Because of the risks, uncertainties and assumptions contained herein, readers should not read forward-looking information as guarantees of future performance or results. Nothing in this presentation is, or should be relied upon as, a promise or representation as to the future. All amounts are in USD unless otherwise noted. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information in this Presentation is made as of the date of this Presentation. MindMed disclaims any intention or obligation to update or revise such information, except as required by applicable law, and MindMed does not assume any liability for disclosure relating to any other company mentioned herein. Investors are cautioned not to unduly rely on this forward-looking information and are encouraged to read MindMed's continuous disclosure documents, including its current annual information form, as well as its audited annual consolidated financial statements which are available on SEDAR at www.sedar.com and on EDGAR at www.sec.gov/edgar.

MindMed's securities have not been approved or disapproved by the SEC or by any state, provincial or other securities regulatory authority, nor has the SEC or any state, provincial or other securities regulatory authority passed on the accuracy or adequacy of this Presentation. Any representation to the contrary is a criminal offense.

Leadership: A Combination of Drug Developers & Technologists

Robert Barrow

Chief Executive Officer

Rob is an accomplished pharmaceutical executive and clinical pharmacologist with over a decade of experience leading drug development programs in a variety of disease areas. Mr. Barrow previously served as Director of Drug Development & Discovery at Usona Institute, where he oversaw preclinical, clinical and regulatory development efforts for all of Usona's development programs. Prior to joining Usona, he served as Chief Operating Officer of Olatec Therapeutics where he oversaw the execution of numerous early- and late-stage clinical trials in the fields of analgesics, rheumatology, immunology and cardiovascular disease. Rob holds a Master's degree in Pharmacology from The Ohio State University and a Bachelor of Science degree from Wake Forest University, where he graduated summa cum laude.

Miri Halperin Wernli, PhD

Executive President & Board Director

Miri co-founded Creso Pharma, a cannabis company, and listed the company on the Australian Stock exchange (ASX) in October 2016. Prior to founding Creso Pharma Dr. Halperin Wernli worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing. Her extensive pharmaceutical industry and biomed research and development experience covers the full spectrum of areas and activities from Preclinical to Clinical Development and Strategy, to Drug Registration and Launch, across several Therapeutic Areas.

Dave Guebert

Chief Financial Officer

Dave Guebert is a CPA, qualified in both Alberta and Pennsylvania, and a Member of the Institute of Corporate Directors. He started his career in 1979 at Deloitte where he qualified for his CPA designations. He went on to serve as the Controller for the XV Olympic Winter Games from 1986 to 1988. Since then has taken on increasing senior roles, acting as Chief Financial Officer for a number of public and private companies, primarily in the technology industry. He currently sits as a board member and Audit Committee Chair for Legend Power Systems (TSXV: LPS), RMMI Inc. (CSE: RMMI) and Quisitive Technology Solutions, Inc. (TSXV: QUIS). From 2010 to 2017, he was board member and Audit Committee Chair of Merus Labs International Inc. (TSX: MSL; NSDQ: MSLI), a specialty pharmaceutical company.

Daniel Karlin, MD, MA

Chief Medical Officer

Dan previously co-founded HealthMode in 2018 and served as CEO until its acquisition by MindMed. Before that, he built and led Clinical, Informatics, and Regulatory Strategy for Pfizer's Digital Medicine and Innovation Research Lab. He also served as Global Clinical Lead for psychiatry clinical compounds at Pfizer. Previously, he was the founder and Chief Medical Officer at Column Health, a leading technology-enabled psychiatry and addiction practice. He is a strategic advisor to multiple big pharma, and digital therapeutic companies. Dan is board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He is an Asst. Prof. of Psychiatry at Tufts University School of Medicine. He graduated with degrees in Neuroscience and Behavior (BA), and Clinical Informatics (MA), Columbia University; Medicine (MD), University of Colorado School of Medicine.

Bradford Cross

Chief Technology Officer

Bradford previously co-founded HealthMode in 2018 and served as its CTO until its acquisition by MindMed. He is a career entrepreneur and investor with 15+ years at the intersection of AI and startups, and finance. Founded Prismatic in 2012, which powered part of LinkedIn's news feed as of 2015. Machine learning for personalization and content classification. Founded DCVC in 2011, which has grown into a $2B+ leading deep tech VC investing heavily at the intersection of computation and bio and spinning up dedicated DCVC bio fund. Founded Flightcaster in 2009, first AI Startup in YCombinator. He previously worked in distributed systems at Google 2007-2009. Brad earned degrees in Computer Science and Finance at Virginia Tech, and Mathematics at Berkeley.

Donald Gehlert, PhD

Chief Scientific Officer

Don has extensive experience in drug discovery and expertise in key functional areas of exploratory development and disease biology. During his career at Lilly, Don led or participated in teams that introduced 19 molecules into the Lilly pipeline including both small and large molecule therapies. He also participated on Phase I and Phase II clinical development teams that designed and delivered translational proof of concept studies in the areas of ADHD, obesity, AUD, depression, pain and migraine. He is a co-author on 182 publications and a co-inventor on 15 issued and pending patents.

Therapeutic Area Selection to Address Massive Unmet Needs

Tactical Capital Allocation to Advance Strategic Success

Targeting Major Psychiatric Disorders

51.5M US adults suffering from mental illness [1]

Increasing Burden over Time

21% One year prevalence of anxiety disorders in US [2]

Statistic pertains to individuals aged 18-64 in the US

Major Driver of Overall Healthcare Costs

$225B Annual cost of mental health in US [15]

Current Treatments are Inadequate

88%
Of OUD patients relapse with buprenorphine discontinuation [3]

59%
Of GAD patients with residual symptoms [4]

13%
Of US Population with uncontrolled pain [5]



This slide contains market and industry data that has been obtained from third party sources. Please refer to "Market and Industry Data" on Slide 2

CH: cluster headache; OUD: Opioid Use Disorder; TRD: Treatment Resistant Depression

MindMed is a Mental Health Company

Rigorously Applied Drug Development Principles to a Novel Drug Class

Target Therapeutic Class	Novel Mechanisms of Action
	Strong potential efficacy signals
	Bridges psychotherapy and pharmacology
	Long history of well-tolerated use in clinical studies
Our Development Approach	Rigorous scientific pursuit of drug approvals
	Robust, diverse and integrated R&D pipeline
	Tech enables market access and scale
	Focus on serving large markets with unmet medical needs



R&D: Research and Development

MindMed is a Mental Health Company

Advancing Therapeutic Improvements across the Full Life Cycle

Discover

NCEs and next generation optimization via acquisition, collaboration, and in-house development to build long-term pipeline

Develop

Consistently adhere to rigorous development pathways to enable worldwide market access

Deploy

Innovative approaches to tech, payers, and providers to facilitate scalability and accessibility **leveraging the current** treatment landscape



Psychedelic-Inspired Medicine Opportunity

Illustrative purposes only

Multiple Generations of Potential Drug Candidates derived from Classic Psychedelics

	CONCEPT	MINDMED APPROACH			
CLASSIC PSYCHEDELICS	• Evidence of potential for positive clinical benefit • Extensive prior human exposure • Well-characterized pharmacology • Potential to accelerate development program	 **DMT**	 **MDMA**	 **PSILOCYBIN**	 **LSD**
2ND GENERATION / OPTIMIZED	• Pharmacologically optimized molecules and dosage forms • Modifications to overcome potential safety liabilities • Intellectual property generation	Prodrugs and analogues	Novel dosage forms	Novel treatment models	Novel administration methods
3RD GENERATION / NCES	• Structural analogues to classic psychedelics • Require full development program • Strongest available intellectual property	 **18-MC**	Novel tryptamines	Novel phenethylamines	Non-hallucinogenic analogues

18-MC: 18-Methoxycoronaridine, DMT: N,N-Dimethyltryptamine, MDMA: 3,4-Methylenedioxymethamphetamine, LSD: Lysergic acid diethylamide

Advancing the Field with Strong IP & Strategic Competitive Moats

Protecting Innovation and Market Potential

Our Patent Positions are Extensive and Diverse

45+ patent applications filed

45+ molecules covered

30+ NCEs covered

10+ Patent applications covering LSD

3+ patent applications covering 18-MC

Strategic Approach to Maximize Market Protection

- Composition of matter
- NCEs/psychedelic analogues
- Unexplored indications
- Optimized formulations with unique PK
- Proprietary methods of manufacturing
- Combination therapies
- AI and ML algorithms
- Innovative dosing protocols
- Physiochemical attributes

18-MC: 18-Methoxycoronaridine, AI: artificial intelligence, IP: intellectual property, LSD: lysergic acid diethylamide, ML: machine learning, NCE: new chemical entity, PK: pharmacokinetic

Science & Background

The Case for Psychedelic-Inspired Therapies

Psychedelic Inspired Medicines: A New Treatment Paradigm

A Strong Case for Psychedelic Research



Global Brain Connectivity

Entropic brain activity



Increased single neuron excitability



Source: [10]
This slide contains market and industry data that has been obtained from third party sources. Please refer to "Market and Industry Data" on Slide 2
5-HT2A: 5-hydroxytryptamine receptor 2A, mV: millivolt, min: minutes

LSD | Extensive Early Phase Characterization

Strong Historical Third Party Clinical Research Presents Opportunity for Accelerated Development

1000+ patients treated in clinical trials

29 published clinical studies of LSD

12 published clinical studies since 2008

Preliminary evidence supporting utility in:

- Anxiety
- Depression
- Alcohol use disorder
- Pain

This slide contains market and industry data that has been obtained from third party sources. Please refer to "Market and Industry Data" on Slide 2
LSD: lysergic acid diethylamide

Characteristics of LSD in Human Dosing



Source: [11]

LSD | Stands Out among the Psychedelic Drug Class Opportunities

Substantial Body of Evidence Supports Efficient Development

LSD: Overlooked & Undervalued

- Single administration with rapid and sustained action
- Robust clinical response in a wide range of conditions
- Part of psychedelic drug class with strong efficacy in preliminary studies
- No required bioactivation for activity
- Highly potent with microgram therapeutic range



Fig. 1. Whole-brain cerebral blood flow maps for the placebo and LSD conditions, plus the difference map (cluster-corrected, $P < 0.05$; $n = 15$).

Source: [12]

This slide contains market and industry data that has been obtained from third party sources. Please refer to "Market and Industry Data" on Slide 2
CBF: cerebral blood flow, LSD: Lysergic acid diethylamide

LSD | Emerging Evidence in Pain & Somatic Disorders

Applications Beyond Psychiatry



Source: [13]
LSD: lysergic acid diethylamide, NMDA: N-methyl-D-aspartate, NSAID: nonsteroidal anti-inflammatory drug
This slide contains market and industry data that has been obtained from third party sources. Please refer to "Market and Industry Data" on Slide 2

Low Dose LSD Increases Pain Tolerance and Decreases Perceived Pain



Source: [14]

Kim Kuypers PhD

Associate Professor, Maastricht University
Leading researcher for repeat, sub-experiential LSD dosing

18-MC | Psychedelic-Inspired NCE: 18-MC

Non-hallucinogenic, non-cardiotoxic congener of ibogaine

18-MC Targets Substance Abuse Disorders via Different Mechanisms than Existing Therapies



18-MC: 18-methoxycoronaridine

18-MC | Psychedelic-Inspired NCE

Non-hallucinogenic, non-cardiotoxic congener of ibogaine

18-MC Reduces Morphine and Cocaine Self-Administration in Animal Models of Substance Use Disorder



18-MC

(mg/kg i.p.)



18-MC

(mg/kg i.p.)

18-MC: 18-methoxycoronaridine, ip: ntraperitoneal, mg/kg: milligram/kilogram

R(-)-MDMA Program | Social Functioning in Autism Spectrum Disorder (ASD)

Significant unmet need for novel therapies to support individuals with ASD

Early Data Suggests Potentially Promising Results:

- In a pilot clinical trial, participants with ASD showed strong and statistically significant improvements in social anxiety and functioning from episodic treatment with MDMA

$461B

economic cost of ASD in the US predicted by 2025[17]

12%

of the US general population experience Social Anxiety Disorder at some point in life[18]



Change over time in LSAS total scores (MDMA n=8 at baseline, n=7 at all other time points; placebo n=4). The primary endpoint occurred 1 month after the second experimental session. The 6-month follow-up visit was 6 months after the primary endpoint. The MDMA group had a greater mean change from baseline than the placebo group at the primary endpoint (P=0.037) and at the 6-month follow-up (P=0.036). The line at LSAS score of 60 represents inclusion criteria minimum score.

Source: [16]

Develop & Discover

Our Robust and Diverse Development Pipeline

Pipeline Diversification Offers Access To Full Potential Of Psychedelic Inspired Medicines

PRE-CLINICAL	PHASE 1	PHASE 2A	PHASE 2B	PHASE 3	COMMERCIAL LAUNCH
Undisclosed Substance use disorder Formulation optimization of psychedelics in brain-targeted liposomes nextage	**18-MC** Substance use disorders **Ongoing** — SAD/MAD Safety and PK	**18-MC** Opioid Withdrawal* **Planned Early 2022** – 2-week, randomized, double-blind, placebo-controlled	**LSD** Generalized Anxiety Disorder* **Planned Late 2021** — 12-week, randomized, controlled, parallel-group, single administration, dose optimization		
Undisclosed Preclinical Generation of novel psychedelic-related compounds for preclinical screening MindShift Compounds	**Mescaline** Phase 1 IIT **Ongoing** — Safety & PK Universitätsspital Basel	**LSD** Adult ADHD **Planned Late 2021** — 6-week, randomized, double-blind, placebo-controlled, parallel-group, twice weekly administration			
R(-)-MDMA **Social functioning / ASD** **Ongoing** — Safety & PK	**DMT** Phase 1 IIT **Ongoing** — Safety & PK Universitätsspital Basel	**LSD** IIT - Anxiety disorders **Ongoing** — Random-order, double-blind, placebo-controlled, cross-over Universitätsspital Basel			
	LSD + Ketanserin Phase 1 IIT **Ongoing** — Safety & PK Universitätsspital Basel	**LSD** IIT - Major Depressive Disorder **Ongoing** — Randomised, double-blind, active-placebo-controlled Universitätsspital Basel			
		LSD Acute Pain **Planned 2022** — Undisclosed design			
		LSD Chronic Pain **Planned 2022** — Undisclosed design			
		LSD IIT - Cluster Headache **Ongoing** — randomized, double-blind, placebo-controlled, two-phase cross-over Universitätsspital Basel			

PSYCHIATRY
ADDICTION
PAIN
NEUROLOGY

*Study in planning

Note: Does not include Phase 1 studies being conducted at UHB with a primary objective related to mechanism of action or cross-molecule comparative PK and/or PD studies

18-MC: 18-methoxycoronaridine, ADHD: attention-deficit/hyperactivity disorder, ASD: autism spectrum disorder, GAD: generalized anxiety disorder, IIT: investigator initiated trial, LSD: lysergic acid diethylamide

Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.

LSD Clinical Development Program

Diversified Strategy Across Development Franchises

This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.
ADHD: attention-deficit/hyperactivity disorder, GAD: generalized anxiety disorder, IIT: investigator initiated study, LSD: lysergic acid diethylamide.

Collaborative Approach for Accelerating Value

Collaborations & Data Acquisition enable Rapid Path to Development With Significantly Less Risk

Exclusive UHB License Agreement

Matthias Liechti, MD, PhD
Professor & Head of Liechti Lab

Universitätsspital Basel

- More than ten years of clinical research on LSD
- Dozens of completed and ongoing psychedelic trials
- Exclusive rights to clinical data on LSD, psilocybin, MDMA, mescaline and DMT

18-MC Advanced by $6.5 million NIDA Grant

- $6.5 million NIDA grant in 2013
- Animal efficacy data across multiple substance use targets
- Extensive preclinical safety characterization

NIH
National Institute on Drug Abuse

Data Rights Acquired from UHB

Completed Phase 1

- LSD PK
- LSD fMRI
- LSD LAM
- LSD LDR
- SERT-Psilocybin
- MDMA-reboxetine interaction
- MDMA-duloxetine interaction
- MDMA-clonidine interaction
- MDMA-carvedilol interaction
- MDMA-doxazosin interaction
- MDMA-methylphenidate interaction
- MDMA-methylphenidate comparison
- MDMA-bupropion interaction
- MDMA-fear extinction
- MDMA-fMRI

Ongoing Phase 1

- LSD MDMA
- LSD Ketanserin
- LSD Psilocybin and Mescaline
- DMT Regimen
- Mescaline dose response
- LSD Psilocybin

Ongoing Phase 2

- LSD for Anxiety Disorders
- LSD for Cluster Headaches
- LSD for Depression

Planned Phase 1

- LSD Bioequivalence
- MDMA-related compounds

LSD: lysergic acid diethylamide; MDMA: 3,4-methylenedioxymethamphetamine; MMT: Maudsley Maintenance; 18-MC: 18-Methoxycoronaridine; NIDA: National Institute on Drug Abuse; SERT: serotonin transporter; fMRI: functional magnetic resonance imaging

R&D Pipeline

Robust pipeline driven by collaborative arrangements

Universitätsspital Basel

- Exclusive rights to completed and ongoing clinical study data
- Execution of Phase 1/2 studies on known and novel psychedelics
- Intended to enable efficient de-risking of new assets

MindShift Compounds

- Portfolio of psychedelic-inspired NCEs
- Screening and lead optimization program ongoing
- Generates multiple patent filings

nextage

- Exclusive collaborative R&D agreement covering psychedelics
- Application of liposome technology to optimize delivery

IP: intellectual property, R&D: research and development

Near-Term and Intermediate Value Drivers

DRUG CANDIDATE	INDICATION	LATE 2021	2022	MILESTONE
PSYCHIATRY FRANCHISE				
LSD — *Project Lucy*	Generalized Anxiety Disorder	●		Open IND & Initiate Phase 2b study
	Anxiety disorders (Universitätsspital Basel)		●	Complete IIT in anxiety disorders
LSD — *Project Flow*	Adult ADHD	●		Initiate Phase 2a proof-of-concept study
R(-)-MDMA	Social functioning / ASD		●	Initiate Phase 1 IIT
ADDICTION FRANCHISE				
18-MC — *Project Layla*	Opioid Use Disorder	●		Complete Phase 1 SAD/MAD study
			●	Initiate Phase 2a proof-of-concept study (Opioid Withdrawal)
PAIN FRANCHISE				
LSD — *Project Angie*	Acute Pain indication		●	Initiate Phase 2 clinical program
	Chronic Pain indication		●	Initiate Phase 1/2 clinical program
NEUROLOGY FRANCHISE				
LSD	Cluster Headache (Universitätsspital Basel)		●	Complete IIT in cluster headache
PRECLINICAL/PHASE 1				
MM-823 (nextage)		●		Formulation development and preclinical proof-of-concept
Mescaline*		●		Initiate Phase 1 IIT (ongoing)
DMT			●	Complete Phase 1 IIT
LSD + Ketanserin			●	Complete Phase 1 IIT

This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.
ADHD: attention deficit hyperactivity disorder, ASD: autism spectrum disorder, DMT: N,N-dimethyltryptamine, IIT: investigator-initiated trial, IND: investigational new drug, LSD: lysergic acid diethylamide, Late 2021: Q3-Q4 2021; MAD: multiple ascending dose, SAD: single ascending dose
*Planned initiation Mid 2021

Deploy

Our Division To Enable Scalability & Accessibility of Our Drug Programs



Commercial Principles for Scalability & Accessibility

Scalable Delivery Platform to Enable Leveraging of Current Ecosystem

Digital Medicine

- Use digital medicine technology to promote outcomes and engagement at all phases of the development, deployment, and clinical lifecycle
- Build proprietary applications to increase patient engagement, enhance provider experience, and protect market share

Building The Psychiatric Training Infrastructure

- Donating $5 million over a 5-year period
- Establish the gold standard of training programs to educate healthcare providers and psychedelic researchers

Innovative Medical Approaches

- Driving adoption of our drugs through enhancement of the existing psychiatric and psychotherapeutic infrastructure
- LSD neutralizer technology
- Value-based reimbursement models

This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.
LSD: lysergic acid diethylamide

Digital Medicine: Multiple components of the MindMed platform

Scalable Delivery Platform to Enable Adoption Leveraging the Current Ecosystem

Early Engagement & Education

- Patient education, engagement, preparation and assistance
- Deep digital diagnosis allows greater granularity to complement DSM diagnoses
- Support for treatment selection: modality dose, and timing



Treatment Session

- In-session monitoring for safety, efficacy, and additional interventions
- Clinician decision support for drug and non-drug therapeutic sessions
- Predictive models linking interventions and treatment outcomes



Longitudinal Patient Engagement

- Real world monitoring of trends for relapse prediction and re-treatment decisions
- Engagement in health maintenance behaviors
- AI models to inform psychotherapeutic intervention

AI: artificial intelligence; DSM: Diagnostic and Statistical Manual of Mental Disorders
This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.
Note: application images are for illustrative purposes only.

Psychedelics Driving Progressive Care and Payment Models

Complementary Digital Medicine Approach for Improved Mental Health Outcomes

Digital Measurement enables value-based clinical models

Driving engagement through friction reducing patient technologies



Drug pricing and reimbursement driven by measured health economics & outcomes research value

High value market for providers enabled by novel reimbursement mechanisms

Digital Measures, Diagnostics & Therapeutics to Enable Commercial Viability

Building Toward Novel Care and Reimbursement Models

1. Build measurement, diagnostic and therapeutic models using real world data
2. Validate measures, diagnostics, and interventions through clinical studies run on internal app channels
3. Next-generation applications support full patient and provider journeys including treatments sessions and intersession monitoring
4. Embedded measures, diagnostics, and therapeutics to enable closed-loop value-based care and evidence for commercialization with payers



*Example only and does not include real patient identifying information or data

This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.
Note: application images are for illustrative purposes only.

Developing Platform to Utilize all Relevant Data Types

Measurement, Diagnostics and Therapeutics

Data	Models	Applications
Audio*	MindMed Machine Learning	Anxiety
Text	Measurements	Addiction
Behavioral*	Diagnostics	PTSD
Genomic	Therapeutics	ADHD
Biological		Pain
Mobile*		
Smartwatch*		
Partner Integrations		

*enabled by HealthMode acquisition

ADHD: attention deficit hyperactivity disorder ; PTSD: post traumatic stress disorder

Digital Platform Pipeline Progression Mirrors Drug Pipeline

Across Product Categories, Progression is Enabled by Technical Development and Clinical Research

TECHNOLOGY CANDIDATE	DISCOVERY & REAL-WORLD DATA	MINIMUM VIABLE PRODUCT & CLINICAL DATA COLLECTION	STUDY USE, ALGORITHM DEVELOPMENT & PRODUCT ENHANCEMENT	VALIDATION & FDA CLEARANCE	COMMERCIAL LAUNCH
Anxiety & Affective Disorders Intrasession SaMD Component #2 **In development** — Concept development	**Anxiety & Affective Disorders** Intrasession Monitoring Platform **In development** — Internal discovery and real world data analysis	**Anxiety Disorders** Intersession Monitoring Platform **Planned Late 2021** — Large decentralized observational study	**Agitation Detection & Prediction** Transdiagnostic **Ongoing** — Multiple Study Environments		
Anxiety & Affective Disorders Intrasession SaMD Component #3 **In development** — Concept development	**Anxiety & Affective Disorders** Intrasession SaMD Component #1 **In development** — Internal discovery real world data analysis	**Substance Use Disorders** Substance Use Detection **Planned Late 2021** — Progress to clinical data collection	**Opioid Use Disorders** Opioid Withdrawal Detection **Planned Late 2021** — Progress to clinical data collection		
Anxiety & Affective Disorders Decision Support Platform **In development** — Concept development		**Acute and Chronic Pain** Pain Measurement System **Ongoing** — Data collection for model development	**Acute and Chronic Pain** Pain Reporting System **Ongoing** — In study Use		
			Parkinson's Disease Tracking Platform **Ongoing** — Mobile Observational study with undisclosed pharma partner		

PSYCHIATRY
PAIN
ADDICTION
NEUROLOGY

SaMD: software as a medical device
Early: Q1-Q2; Mid: Q2-Q3, Late: Q3-Q4
This slide contains forward-looking information. Please refer to "Cautionary Note on Forward-Looking Information" on Slide 2.

Corporate Information

NASDAQ: MNMD // NEO: MMED // DE: MMQ

First Publicly Listed Psychedelic Biotech Company

Share Ownership *as of July 31, 2021*		
Executive Team/Directors/Insiders	65,468,007	13.8%
Non-insider shares	351,330,630	74.2%
Equity Incentive Plan (Issued)	33,082,892	7.0%
Outstanding Warrants	23,387,631	4.9%
Total (Fully diluted)	473,269,160	100%

Nasdaq

NEO

Market Cap: USD $1.05 billion Nov 16, 2021 ($2.35 per share)

Market Cap: C$1.39 billion Nov 16, 2021 (C$2.93 per share)

$204 million

Raised since inception *including warrants*

$146 million

Cash position *as of September 30, 2021*

Scientific Advisors: World Class Expert Support

Robert Malenka, MD, PhD

Chairman of the Scientific Advisory Board, Nancy Friend Pritzker Professor in Psychiatry and Behavioral Sciences at Stanford University

Maurizio Fava, MD

Member, Scientific Advisory Board Psychiatrist-in-Chief of the Massachusetts General Hospital (MGH)

Peter Bergethon, MD

Member, Scientific Advisory Board VP, Head of Quantitative & Clinical Technologies, Biogen, Inc.

Robert H. Dworkin, PhD

Professor of Anesthesiology and Perioperative Medicine, Neurology, and Psychiatry, and Professor in the Center for Health + Technology, at the University of Rochester School of Medicine and Dentistry

Bryan Roth, MD, PhD

Michael Hooker Distinguished Professor, NIMH Psychoactive Drug Screening Program

Matthew Johnson, PhD

Professor at Johns Hopkins

Jed Rose, PhD

Professor in Psychiatry and Behavioral Sciences at Duke University

John Blacker, PhD

Professor of Process Chemistry, University of Leeds

John Rotrosen, MD

Professor of Psychiatry NYU Langone

Kenneth Alper, MD

Clinical Associate Professor of Psychiatry and Neurology, NYU Langone

Sarah McCallum, PhD

Associate Professor of Neuroscience and Experimental Therapeutics

Stanley Glick, PhD

Scientific Advisor for 18-MC

Board of Directors

Perry Dellelce

Chairman of the Board of Directors

Perry Dellelce is a managing partner of Wildeboer Dellelce LLP. He also serves as chair of the NEO Exchange, Canada's newest stock exchange. Board Member of Mount Logan Capital Inc. and Lendified Inc.

Miri Halperin Wernli, PhD

Executive President, Director

Dr. Halperin Wernli previously worked in clinical psychiatry in Swiss academic hospital settings and then held various global senior leadership positions in the pharma and biotech industries in Switzerland and in the US (Merck, Sharp and Dohme, Roche and Actelion pharmaceuticals) covering Product Development, R&D, and Strategic Marketing.

Stephen Hurst, JD

Co-Founder and Director

Stephen Hurst has more than thirty-five years' experience in the biopharmaceutical industry including work for The Immune Tolerance Institute, The Regents of the University of California, The World Bank and BIO Ventures for Global Health.

Carol Vallone

Director

Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies. Currently, she serves as Chair of the Board of Trustees at McLean Hospital, the #1 ranked freestanding psychiatric hospital and largest psychiatric affiliate of Harvard Medical School; serves on the board of trustees at MGH Institute of Health Professions; and serves on the finance committee at Mass General Brigham.

Andreas Krebs

Director

Mr. Krebs heads the family-owned investment company Longfield Invest (Langenfeld/Germany), which focuses on growth companies in various industries as well as in the new economy. He was formerly Executive Board Member of Wyeth Corporation in the United States. Andreas Krebs was Chairman of the Supervisory Board and Shareholder Council of Merz Pharma, Frankfurt am Main, Germany from 2010 to 2019, is currently a member of the Supervisory Board of the European eye clinic group Veonet (Nordic Capital Group) and holds other board positions across various sectors.

Brigid Makes

Director, Chair of Audit Committee

Brigid Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs. Former CFO for Nektar Therapeutics (formerly Inhale Therapeutics) B.A. in Finance and International Business from McGill University and an M.B.A. from Bentley University. Brigid chairs the board's Audit Committee.

Sarah Vinson, MD

Director

Dr. Vinson is a Triple Board-Certified physician who specializes in adult, child & adolescent, and forensic psychiatry. She is the founder of Lorio Forensics. Dr. Vinson is an Associate Clinical Professor of Psychiatry and Pediatrics at Morehouse School of Medicine, where she is the Program Director of the Child & Adolescent Psychiatry Fellowship, and Adjunct Faculty at Emory University School of Medicine.

Public Perception of Psychedelics Has Changed

THE WALL STREET JOURNAL.

"Psychedelics-Drug Startup Raises $24 Million Ahead of IPO." February 27, 2020

Bloomberg

"Its market capitalization of over C$1 billion puts the company ahead of at least eight companies in Canada's benchmark S&P/TSX Composite Index, according to data compiled by Bloomberg." December 9, 2020

BUSINESS INSIDER

"A startup that wants to use psychedelics to treat addiction just raised $6.2 million from the host of. Shark Tank and the architect behind the world's. biggest cannabis grower" September 30, 2019

FAST COMPANY

"This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn't I want to be invested?" -Kevin O' Leary December 9, 2019

THE NEW YORKER

"New York is getting its first psychedelic-medicine center, with the help of a startup called MindMed, which develops hallucinogens to treat mental illness and addiction, and is funding an institute at N.Y.U. Langone Medical Center." October 12, 2020

FORTUNE

"Psychedelic drugs may transform mental health care. And big business is ready to profit from the revolution." February 17, 2020

Forbes

"Psychedelic Drug Company MindMed Applies For NASDAQ Up-Listing" September 25, 2020

TOWN&COUNTRY

"The evidence for psychedelics as medicine is far greater than that for CBD, which companies are selling to relieve ills from Parkinson's to Crohn's." April 13, 2020

"MindMed named one of 36 startups that could change the world" *December 17, 2019*

MindMed

Sources

1. Mental Health By the Numbers | NAMI: National Alliance on Mental Illness. (2019). NAMI. https://www.nami.org/mhstats#:%7E:text=20.6%25%20of%20U.S.%20adults%20experienced,represents%201%20in%2020%20adult
2. Bandelow, Borwin, and Sophie Michaelis. "Epidemiology of anxiety disorders in the 21st century." Dialogues in clinical neuroscience vol. 17,3 (2015): 327-35.
3. Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., Gardin, J., Griffin, M. L., Gourevitch, M. N., Haller, D. L., Hasson, A. L., Huang, Z., Jacobs, P., Kosinski, A. S., Lindblad, R., McCance-Katz, E. F., Provost, S. E., Selzer, J., Somoza, E. C., Sonne, S. C., … Ling, W. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Archives of general psychiatry, 68(12), 1238–1246. https://doi.org/10.1001/archgenpsychiatry.2011.121
4. Kelly, K. M., & Mezuk, B. (2017). Predictors of remission from generalized anxiety disorder and major depressive disorder. Journal of affective disorders, 208, 467–474. https://doi.org/10.1016/j.jad.2016.10.042
5. Dahlhamer, J., Lucas, J., Zelaya, C., Nahin, R., Mackey, S., DeBar, L., Kerns, R., Von Korff, M., Porter, L., & Helmick, C. (2018). Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults - United States, 2016. MMWR. Morbidity and mortality weekly report, 67(36), 1001–1006. https://doi.org/10.15585/mmwr.mm6736a2
6. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018;75(4):336–346. doi:10.1001/jamapsychiatry.2017.4602
7. 2019 National Survey on Drug Use and Health, 2020
8. Dahlhamer J, Lucas J, Zelaya, C, et al. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults — United States, 2016. MMWR Morb Mortal Wkly Rep 2018;67:1001–1006. DOI: http://dx.doi.org/10.15585/mmwr.mm6736a2external icon.
9. Wei DY, Yuan Ong JJ, Goadsby PJ. Cluster Headache: Epidemiology, Pathophysiology, Clinical Features, and Diagnosis. Ann Indian Acad Neurol. 2018;21(Suppl 1):S3-S8. doi:10.4103/aian.AIAN_349_17
10. Carhart-Harris RL, Leech R, Hellyer PJ, et al. The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci. 2014;8:20. Published 2014 Feb 3. doi:10.3389/fnhum.2014.00020
11. Holze, F., Vizeli, P., Ley, L. et al. Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacol. 46, 537–544 (2021). https://doi.org/10.1038/s41386-020-00883-6
12. Carhart-Harris RL, Muthukumaraswamy S, Roseman L, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci U S A. 2016;113(17):4853-4858. doi:10.1073/pnas.1518377113
13. Dureja GP, Iyer RN, Das G, Ahdal J, Narang P. Evidence and consensus recommendations for the pharmacological management of pain in India. J Pain Res. 2017;10:709-736. Published 2017 Mar 29. doi:10.2147/JPR.S128655
14. Ramaekers, J. G., Hutten, N., Mason, N. L., Dolder, P., Theunissen, E. L., Holze, F., Liechti, M. E., Feilding, A., & Kuypers, K. P. (2021). A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. Journal of psychopharmacology (Oxford, England), 35(4), 398–405.13
15. M.I. (2020, May 6). The U.S. Mental Health Market: $225.1 Billion In Spending In 2019: An OPEN MINDS Market Intelligence Report. OPEN MINDS. https://openminds.com/intelligence-report/the-u-s-mental-health-market-225-1-billion-in-spending-in-2019-an-open-minds-market-intelligence-report/
16. Danforth, A. L., Grob, C. S., Struble, C., Feduccia, A. A., Walker, N., Jerome, L., Yazar-Klosinski, B., & Emerson, A. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology, 235(11), 3137–3148. https://doi.org/10.1007/s00213-018-5010-9
17. Autism Statistics and Facts. (2017). Autism Speaks. https://www.autismspeaks.org/autism-statistics-asd
18. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry. 2005;62:593–602.